COMP <GO>
EYE vs ABBV // GROSS PROFIT MARGIN
National Vision Holdings Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: EYE 4
— ABBV 6
■ METRIC PARITY
LAST: $16.64 (+7.63%) • MKT CAP: $1.32B
gross-margins
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EYE VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EYE | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.40% | 29.00% | -24.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.4x | 33.3x | -20.90 | EYE | /valuation <GO> |
| Free Cash Flow Yield | 5.58% | 3.47% | +2.11 | EYE | /fcf-yield <GO> |
| Operating Margin | 3.00% | 24.60% | -21.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 1.50% | 6.90% | -5.40 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 9.00% | 8.60% | +0.40 | EYE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.33 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.6 | 65.1 | -19.50 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 41.3x | 113.1x | -71.80 | EYE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.32B | $513.86B | -$512.54B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EYE REV | ABBV REV | EYE GROSS % | ABBV GROSS % | EYE FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.99B | $61.16B | — | 70.2% | $73.5M | $17.82B |
| FY 2024 | $1.82B | $56.33B | — | 70.0% | $38.1M | $17.83B |
| FY 2023 | $1.76B | $54.32B | — | — | $173.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EYE // BETA —
ABBV // BETA 1.15